1,224
Views
19
CrossRef citations to date
0
Altmetric
Letters to the Editor

Rituximab and Acute Retinal Necrosis in a Patient with Scleromalacia and Rheumatoid Arthritis

, MD, , MD & , MD
Pages 96-98 | Received 26 Aug 2014, Accepted 14 Dec 2014, Published online: 11 Mar 2015

Figures & data

FIGURE 1. Scleromalacia located in the upper area of the temporal bulbar quadrant. (a). Note the loss of scleral tissue centrally and a change of transparency in the adjacent tissue, visible as a bluish discoloration. (b). The same eye is shown 8 years later with marked progression of the scleromalacia and a bulging staphyloma.

FIGURE 1. Scleromalacia located in the upper area of the temporal bulbar quadrant. (a). Note the loss of scleral tissue centrally and a change of transparency in the adjacent tissue, visible as a bluish discoloration. (b). The same eye is shown 8 years later with marked progression of the scleromalacia and a bulging staphyloma.

FIGURE 2. Fundoscopic photograph of the same eye with hemorrhagic occlusive vasculitis and confluent whitish areas of retinal necrosis in the peripheral ocular fundus. Note the central involvement with macular hemorrhage.

FIGURE 2. Fundoscopic photograph of the same eye with hemorrhagic occlusive vasculitis and confluent whitish areas of retinal necrosis in the peripheral ocular fundus. Note the central involvement with macular hemorrhage.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.